Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Peptech and EvoGenix merge to form antibody powerhouse
June 2007
SHARING OPTIONS:

SYDNEY, Australia—Peptech Ltd. and antibody therapeutics company, EvoGenix Ltd. recently announced plans to merge, to form one company poised to become a high-profile player in the worldwide antibody and protein therapeutics sector.
 
The merged company will be led by Peptech CEO, Dr. John Chiplin, and a board made up of directors from both companies. Dr Merilyn Sleigh, EvoGenix CEO, will be retained in a senior advisory role.
 
The focus of the company is on developing significant antibody/protein based franchises for the treatment of inflammatory diseases, bone disease and cancer. Each of these therapeutic areas represent substantial opportunities with successful antibody-based products achieving record sales growth in recent years to levels in excess of $1 billion dollars annually.
 
"Consistent with our previously announced strategy, this transaction creates a combined entity which is poised to be a major player on the worldwide antibody stage," says Chiplin. "We have built critical mass...to compete aggressively in the fastest growing sector of the international human therapeutic market. EvoGenix and Peptech are an excellent strategic fit. EvoGenix has revenue-generating technology with proven capabilities and linkages that blend ideally with our own product development activities, to deliver more rapid company growth and delivery of products to the clinic."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.